<p>极地资产管理合伙公司在最近向证券交易委员会提交的 13F 表格中表示，在第四季度购买了强生公司（NYSE:JNJ - 免费报告）的新股份。该公司购买了 270,000 股，价值约为 39,047,000 美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>3 适合长期投资者在任何市场中持有的股票</li>
</ul>
<p>其他几家对冲基金最近也调整了对 JNJ 的持股。WealthTrak Capital Management LLC 在第四季度购买了强生公司的新股份，价值约为 26,000 美元。Mountain Hill Investment Partners Corp.在第四季度购买了强生公司的新股份，价值约为 29,000 美元。Bay Harbor Wealth Management LLC 在第四季度购买了强生公司的新股份，价值约为 32,000 美元。Conquis Financial LLC 在第四季度购买了强生公司的新股份，价值约为 33,000 美元。最后，Bernard Wealth Management Corp.在第四季度购买了强生公司的新股份，价值约为 36,000 美元。机构投资者持有该公司 69.55% 的股份。</p>
<h2>强生公司的内部交易</h2>
<p>在其他新闻中，副总裁 Robert J. Decker 于 2 月 25 日星期二出售了 6,999 股强生公司的股票。股票以 165.88 美元的平均价格出售，总交易额为 1,160,994.12 美元。出售完成后，该副总裁现在直接持有 21,001 股公司的股票，价值约为 3,483,645.88 美元。此次交易使其持股减少了 25.00%。该交易已在向 SEC 的法律文件中披露，相关信息可通过此链接访问。当前 0.16% 的股票由内部人士持有。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>3 家行业巨头正在通过分红提升回报</li>
</ul>
<p>几位股票研究分析师最近对该股票发布了报告。Leerink Partners 在 5 月 13 日的研究报告中将强生公司的股票评级从 “强力买入” 下调至 “持有”。美国银行在 4 月 10 日的研究报告中将强生公司的股票目标价从 171.00 美元下调至 159.00 美元，并对该公司设定了 “中性” 评级。加拿大皇家银行在 4 月 16 日的研究报告中重申了 “跑赢大盘” 的评级，并对强生公司的股票设定了 181.00 美元的目标价。高盛集团在 4 月 9 日的研究报告中将强生公司的股票评级从 “中性” 上调至 “买入”，并将其目标价从 157.00 美元提高至 172.00 美元。最后，古根海姆在 4 月 2 日的研究报告中重申了对强生公司的股票的 “中性” 评级。共有 11 位分析师对该股票给予了持有评级，8 位给予了买入评级，2 位给予了强力买入评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 170.88 美元。</p>
<p><strong>获取我们对强生公司的最新分析</strong></p>
<h2>强生公司股票上涨 0.3%</h2>
<ul>
<li>3 家在美国投资超过 1000 亿美元的顶级制药公司股票</li>
</ul>
<p>强生公司（NYSE:JNJ）周五开盘价为 153.12 美元。该公司的 50 日移动平均价格为 155.24 美元，200 日移动平均价格为 153.69 美元。公司的债务与股本比率为 0.43，流动比率为 1.11，速动比率为 0.86。强生公司的股价一年低点为 140.68 美元，一年高点为 169.99 美元。该公司的市值为 3684.1 亿美元，市盈率为 23.02，PEG 比率为 2.56，贝塔值为 0.42。</p>
<p>强生公司（NYSE:JNJ - 获取免费报告）最近在 4 月 15 日星期二发布了季度财报。该公司报告每股收益（EPS）为 2.77 美元，超过分析师共识预期的 2.59 美元，超出 0.18 美元。强生公司的净利润率为 18.20%，股本回报率为 34.24%。该公司在本季度的收入为 218.9 亿美元，而共识预期为 216.5 亿美元。分析师预计强生公司在当前财政年度的每股收益将达到 10.58 美元。</p>
<h2>强生公司增加分红</h2>
<p>该公司最近还披露了季度分红，将于 6 月 10 日星期二支付。5 月 27 日星期二的股东将获得每股 1.30 美元的分红。这比强生公司之前的季度分红 1.24 美元有所增加。这相当于每年 5.20 美元的分红，分红收益率为 3.40%。该分红的除息日为 5 月 27 日星期二。强生公司的派息比率目前为 57.84%。</p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生公司是一家控股公司，专注于医疗领域的产品研究、开发、生产和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票超过强生公司</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>Trade Desk 沉默批评者；复苏似乎有望继续</li>
<li>标普 500 指数是什么，它与其他指数有何不同</li>
<li>Booz Allen Hamilton 财报：BAH 股票的 3 个看涨信号</li>
<li>消费者价格指数测量什么？</li>
<li>这些 ETF 提供了对不断增长的国际市场的便捷投资机会</li>
</ul>
<p><strong>想看看其他对冲基金持有的 JNJ 股票吗？</strong> 访问 HoldingsChannel.com 获取强生公司（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Polar Asset Management Partners Inc. 在第四季度通过收购 270,000 股强生（NYSE: JNJ）股票进行了约 3905 万美元的新投资。随着其他几家对冲基金也增加了对该公司的持股，这项投资显得尤为重要。强生的股票在分析师中获得了褒贬不一的评级，市场共识目标价为 170.88 美元。该公司最近公布了强劲的季度收益，超出了分析师的预期，并宣布每股派发季度股息 1.30 美元</p>

<p>Polar Asset Management Partners Inc. bought a new position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 270,000 shares of the company's stock, valued at approximately $39,047,000.</p>
<div class="lb-trans"><p>极地资产管理合伙公司在最近向证券交易委员会提交的 13F 表格中表示，在第四季度购买了强生公司（NYSE:JNJ - 免费报告）的新股份。该公司购买了 270,000 股，价值约为 39,047,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market</li>
</ul>
<div class="lb-trans"><ul>
<li>3 适合长期投资者在任何市场中持有的股票</li>
</ul>
</div><p>Several other hedge funds have also recently modified their holdings of JNJ. WealthTrak Capital Management LLC bought a new position in shares of Johnson &amp; Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson &amp; Johnson during the 4th quarter worth approximately $29,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson &amp; Johnson during the 4th quarter worth approximately $32,000. Conquis Financial LLC bought a new position in shares of Johnson &amp; Johnson during the 4th quarter worth approximately $33,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Johnson &amp; Johnson during the 4th quarter worth approximately $36,000. Institutional investors own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也调整了对 JNJ 的持股。WealthTrak Capital Management LLC 在第四季度购买了强生公司的新股份，价值约为 26,000 美元。Mountain Hill Investment Partners Corp.在第四季度购买了强生公司的新股份，价值约为 29,000 美元。Bay Harbor Wealth Management LLC 在第四季度购买了强生公司的新股份，价值约为 32,000 美元。Conquis Financial LLC 在第四季度购买了强生公司的新股份，价值约为 33,000 美元。最后，Bernard Wealth Management Corp.在第四季度购买了强生公司的新股份，价值约为 36,000 美元。机构投资者持有该公司 69.55% 的股份。</p>
</div><h2>Insider Transactions at Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>强生公司的内部交易</h2>
</div><p>In other news, VP Robert J. Decker sold 6,999 shares of Johnson &amp; Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. The trade was a 25.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，副总裁 Robert J. Decker 于 2 月 25 日星期二出售了 6,999 股强生公司的股票。股票以 165.88 美元的平均价格出售，总交易额为 1,160,994.12 美元。出售完成后，该副总裁现在直接持有 21,001 股公司的股票，价值约为 3,483,645.88 美元。此次交易使其持股减少了 25.00%。该交易已在向 SEC 的法律文件中披露，相关信息可通过此链接访问。当前 0.16% 的股票由内部人士持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>3 Industry Behemoths Are Rewarding Investors With Dividend Bumps</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家行业巨头正在通过分红提升回报</li>
</ul>
</div><p>Several equities research analysts have recently issued reports on the stock. Leerink Partnrs lowered shares of Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, May 13th. Bank of America decreased their price target on shares of Johnson &amp; Johnson from $171.00 to $159.00 and set a &#34;neutral&#34; rating for the company in a research note on Thursday, April 10th. Royal Bank of Canada restated an &#34;outperform&#34; rating and set a $181.00 price target on shares of Johnson &amp; Johnson in a research note on Wednesday, April 16th. The Goldman Sachs Group upgraded shares of Johnson &amp; Johnson from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and raised their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Finally, Guggenheim restated a &#34;neutral&#34; rating on shares of Johnson &amp; Johnson in a research note on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $170.88.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发布了报告。Leerink Partners 在 5 月 13 日的研究报告中将强生公司的股票评级从 “强力买入” 下调至 “持有”。美国银行在 4 月 10 日的研究报告中将强生公司的股票目标价从 171.00 美元下调至 159.00 美元，并对该公司设定了 “中性” 评级。加拿大皇家银行在 4 月 16 日的研究报告中重申了 “跑赢大盘” 的评级，并对强生公司的股票设定了 181.00 美元的目标价。高盛集团在 4 月 9 日的研究报告中将强生公司的股票评级从 “中性” 上调至 “买入”，并将其目标价从 157.00 美元提高至 172.00 美元。最后，古根海姆在 4 月 2 日的研究报告中重申了对强生公司的股票的 “中性” 评级。共有 11 位分析师对该股票给予了持有评级，8 位给予了买入评级，2 位给予了强力买入评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 170.88 美元。</p>
</div><p><strong>Get Our Latest Analysis on Johnson &amp; Johnson</strong></p>
<div class="lb-trans"><p><strong>获取我们对强生公司的最新分析</strong></p>
</div><h2>Johnson &amp; Johnson Stock Up 0.3%</h2>
<div class="lb-trans"><h2>强生公司股票上涨 0.3%</h2>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家在美国投资超过 1000 亿美元的顶级制药公司股票</li>
</ul>
</div><p>Shares of NYSE:JNJ opened at $153.12 on Friday. The firm has a fifty day moving average price of $155.24 and a two-hundred day moving average price of $153.69. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson &amp; Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a market cap of $368.41 billion, a price-to-earnings ratio of 23.02, a PEG ratio of 2.56 and a beta of 0.42.</p>
<div class="lb-trans"><p>强生公司（NYSE:JNJ）周五开盘价为 153.12 美元。该公司的 50 日移动平均价格为 155.24 美元，200 日移动平均价格为 153.69 美元。公司的债务与股本比率为 0.43，流动比率为 1.11，速动比率为 0.86。强生公司的股价一年低点为 140.68 美元，一年高点为 169.99 美元。该公司的市值为 3684.1 亿美元，市盈率为 23.02，PEG 比率为 2.56，贝塔值为 0.42。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson &amp; Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Analysts anticipate that Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>强生公司（NYSE:JNJ - 获取免费报告）最近在 4 月 15 日星期二发布了季度财报。该公司报告每股收益（EPS）为 2.77 美元，超过分析师共识预期的 2.59 美元，超出 0.18 美元。强生公司的净利润率为 18.20%，股本回报率为 34.24%。该公司在本季度的收入为 218.9 亿美元，而共识预期为 216.5 亿美元。分析师预计强生公司在当前财政年度的每股收益将达到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Increases Dividend</h2>
<div class="lb-trans"><h2>强生公司增加分红</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is an increase from Johnson &amp; Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson &amp; Johnson's payout ratio is currently 57.84%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 6 月 10 日星期二支付。5 月 27 日星期二的股东将获得每股 1.30 美元的分红。这比强生公司之前的季度分红 1.24 美元有所增加。这相当于每年 5.20 美元的分红，分红收益率为 3.40%。该分红的除息日为 5 月 27 日星期二。强生公司的派息比率目前为 57.84%。</p>
</div><h2>Johnson &amp; Johnson Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生公司是一家控股公司，专注于医疗领域的产品研究、开发、生产和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>Trade Desk Silences Critics; Recovery Looks Poised to Continue</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock</li>
<li>What does consumer price index measure?</li>
<li>These ETFs Provide Easy Exposure to Growing International Markets</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过强生公司</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>Trade Desk 沉默批评者；复苏似乎有望继续</li>
<li>标普 500 指数是什么，它与其他指数有何不同</li>
<li>Booz Allen Hamilton 财报：BAH 股票的 3 个看涨信号</li>
<li>消费者价格指数测量什么？</li>
<li>这些 ETF 提供了对不断增长的国际市场的便捷投资机会</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 JNJ 股票吗？</strong> 访问 HoldingsChannel.com 获取强生公司（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Polar Asset Management Partners Inc. 在强生公司（NYSE: JNJ）进行了新的 3905 万美元投资